Are You Overpaying For Regeneron Stock Versus Its Rivals?
For questions about this article or underlying research, email help@trefis.com. Regeneron Pharmaceuticals (REGN) grew revenue 9.3% over its latest four fiscal quarters. That pace outstripped four of the five large drugmakers in its peer group. Its price ranks lower. Counting Regeneron, four companies in the table had no quarterly loss. Among them, Regeneron has the […]